HBV相关性HCC和HBV感染的过继性T细胞疗法。

StephenW

Antiviral Res. 2020 Feb 19:104748. doi: 10.1016/j.antiviral.2020.104748. [Epub ahead of print]
Adoptive T-cell therapy for HBV-associated HCC and HBV infection.
Tan AT1, Schreiber S2.
Author information

1
    Emerging Infectious Diseases Programme, DUKE-NUS Medical School, Singapore. Electronic address: [email protected].
2
    Institute of Virology, Technical University of Munich/Helmholtz Zentrum München, Munich, Germany.

Abstract

Chronic hepatitis B virus (HBV) infection remains a major global concern due to its high prevalence and the increased probability of progressing toward cirrhosis and hepatocellular carcinoma (HCC). While currently available therapies are effective in controlling HBV replication, they rarely achieve functional cure. Similarly, effective treatment options for HBV-related HCC (HBV-HCC) are limited and primarily applicable only for early stages of the disease. With the general success of chimeric antigen receptor T-cell immunotherapy against B-cell leukemia, adoptively transferring engineered autologous T cells specific for HBV or HCC antigens might represent a promising therapeutic approach for both chronic HBV infection and HBV-HCC. This review will describe the novel T cell-related immunotherapies being developed for both indications and discuss the approach of each strategy, their considerations and limitations when applied for treatment of chronic HBV infection (CHB) and HBV-HCC.

Copyright © 2020. Published by Elsevier B.V.

PMID:
    32087191
DOI:
    10.1016/j.antiviral.2020.104748

StephenW

抗病毒水库。 2020 Feb 19：104748。 doi：10.1016 / j.antiviral.2020.104748。 [Epub提前发行]
HBV相关性HCC和HBV感染的过继性T细胞疗法。
Tan AT1，Schreiber S2。
作者信息

1个
    新加坡杜克国大医学院新兴传染病计划。电子地址：[email protected]。
2
    慕尼黑工业大学病毒学研究所/德国慕尼黑Helmholtz ZentrumMünchen。

抽象

慢性乙型肝炎病毒（HBV）感染由于其高流行和发展为肝硬化和肝细胞癌（HCC）的可能性增加而仍然是全球关注的主要问题。虽然当前可用的疗法可有效控制HBV复制，但很少能达到功能治愈。同样，针对HBV相关性HCC（HBV-HCC）的有效治疗选择是有限的，并且主要仅适用于疾病的早期阶段。随着针对B细胞白血病的嵌合抗原受体T细胞免疫疗法的普遍成功，过继转移对HBV或HCC抗原特异的工程化自体T细胞可能代表着一种有前途的慢性HBV感染和HBV-HCC治疗方法。这篇综述将描述针对这两种适应症而开发的新型T细胞相关免疫疗法，并讨论每种策略的方法，其在用于治疗慢性HBV感染（CHB）和HBV-HCC时的考虑因素和局限性。

版权所有©2020。由Elsevier B.V.发布。

PMID：
    32087191
DOI：
    10.1016 / j.antiviral.2020.104748